Clinical Trials Recruiting near Palo Alto, CA

1,001 clinical trials have a recruiting site within 25 miles of Palo Alto, California, according to ClinicalTrials.gov data processed October 15, 2026. The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Recruiting now

Studies enrolling near Palo Alto

Showing 30 studies, nearest first.

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
- Observational
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
21 sites within 25 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
18 sites within 25 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
- Phase 3
- Ages 18 to 60 years
- Sex: Female
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
18 sites within 25 mi
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
18 sites within 25 mi
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
- Phase 3
- Ages 50 to 70 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
15 sites within 25 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
11 sites within 25 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
10 sites within 25 mi
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
- Phase 3
- Ages 18 years and older
- Sex: Male
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
9 sites within 25 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT06876714
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
9 sites within 25 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
8 sites within 25 mi
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
8 sites within 25 mi
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
8 sites within 25 mi
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03150693
- Phase 3
- Ages 18 to 39 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NCT05408845
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT06029270
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074
- Phase 3
- Ages 18 years and older
- Sex: Female
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
7 sites within 25 mi
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
6 sites within 25 mi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
6 sites within 25 mi
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535
- Phase 2
- Ages 12 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
5 sites within 25 mi
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
5 sites within 25 mi
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
NCT05058651
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
- Phase 2
- Ages 18 Minutes and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
NCT06866405
- Phase 3
- Ages 0 years and older
- Sex: All
- Accepts healthy volunteers
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
4 sites within 25 mi

By condition

Clinical trials in Palo Alto by condition

Source: ClinicalTrials.gov, data processed October 15, 2026. Recruiting US sites filtered by distance and site status; summaries shortened.